- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 401/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
Patent holdings for IPC class C07D 401/08
Total number of patents in this class: 253
10-year publication summary
|
9
|
13
|
16
|
25
|
14
|
20
|
12
|
26
|
10
|
10
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Nxera Pharma UK Limited | 167 |
18 |
| Assembly Biosciences, Inc. | 79 |
10 |
| Pfizer Inc. | 3371 |
9 |
| Bristol-myers Squibb Company | 4880 |
7 |
| Janssen Pharmaceutica N.V. | 3394 |
6 |
| Merck Patent GmbH | 5815 |
6 |
| F. Hoffmann-La Roche AG | 7947 |
5 |
| AstraZeneca AB | 2892 |
5 |
| Incyte Holdings Corporation | 666 |
5 |
| Karyopharm Therapeutics Inc. | 141 |
5 |
| Merck Sharp & Dohme LLC | 3751 |
5 |
| Cytokinetics, Inc. | 279 |
4 |
| Heptares Therapeutics Limited | 76 |
4 |
| Incyte Corporation | 1022 |
4 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 829 |
4 |
| Taro Pharmaceuticals Inc. | 34 |
4 |
| Universite de Rouen | 104 |
4 |
| Incyte Holdings Corporation and Incyte Corporation | 82 |
4 |
| Takeda Pharmaceutical Company Limited | 2708 |
3 |
| Vertex Pharmaceuticals Incorporated | 1600 |
3 |
| Other owners | 138 |